Omicron is out competing omicron

Current symptoms

Runny nose, 73%

Headache, 68%

Fatigue, 64%

Sneezing, 60%

Sore throat, 60%

Persistent cough, 44%

Hoarse voice, 36%

Chills or shivers, 30%

Fever, 29%

Dizzy, 28%

Brain fog, 24%

Altered smell, 23%

Sore eyes, 23%

Unusual muscle pains, 23%

Skipped meals, 21%

Loss of smell, 19%

Chest pain, 19%

Swollen glands, 19%

Feeling down, 16%
ONS

[ Ссылка ]

[ Ссылка ]

Prevalence, week ending 22 January 2022

England, 2,629,400 people, 1 in 20

Wales, 99,500 people, 1 in 30

Scotland, 163,600 people, 1 in 30

Northern Ireland, 96,500 people, 1 in 20

Double vaccinated less likely to report long COVID

Compared to unvaccinated when infected

41.1% decrease in the likelihood of self-reported long COVID at least 12 weeks later

Risk of COVID-19 death higher for most ethnic minority groups

Risk of death involving COVID-19 was higher for people from all ethnic minority groups,

except for Chinese men and women

Bangladeshi group

Women, 5.2 times higher than White British group

Men, 4.4 times higher than White British group

Zoe, Omicron bounces back

[ Ссылка ]

159,486 new daily symptomatic cases of COVID in the UK

An increase of 10% from 144,527 reported last week

UK R value, around 1.0

Prevalence

One in 30 people in the UK currently have symptomatic COVID

Professor Tim Spector

End of school holidays repeatedly usher in a rapid rise in cases among children

A new subtype of Omicron is taking over called BA.2

One in 20 new cases had this variant last week, and as it's doubling every few days,

this should predominate within a month.

Natural infection with Delta may not offer much protection.

I expect that cases will continue to stay high until spring.

Most vaccinated infections are mild,

with symptoms lasting on average for a shorter time than Delta

with less severe cases.

Vulnerable groups

UK data

[ Ссылка ]

US cases and deaths data

[ Ссылка ]

South Africa references

[ Ссылка ]

[ Ссылка ]

свернуть